Pharmacokinetic and bioequivalence study of two gemfibrozil preparations

Sarolta Benkö, Sándor Drabant, Gyula Grézal, Iván Ürmös, Margit Csörgö, I. Klebovich

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

A comparative pharmacokinetic study has been performed in 19 healthy male volunteers in a single-dose, randomized, two way cross-over design with two preparations of gemfibrozil (CAS 25812-30-0) capsules each of them containing 300 mg active ingredient. The test preparation was Innogem® 300 mg capsule. The plasma concentration of gemfibrozil was determined by a validated HPLC-UV analytical method. The statistical comparison of individual pharmacokinetic parameters (AUC0-16, AUC(0-∞), C(max), t(max)) Of the two capsule preparations was performed by three-way analysis of variance (ANOVA), Wilcoxon's, Westlake's, Schuirmann's and Hauck-Anderson's method as well as by the calculation of confidence intervals on the ratio of test/reference. The relativ bioavailability of the test preparation with respect to the reference preparation in terms of the AUC(0-∞) was 104.06 ± 21.61%. No statistically significant difference was found between the pharmacokinetic parameters, calculated from plasma concentration-time curves, indicating that the two preparations were bioequivalent.

Original languageEnglish
Pages (from-to)913-916
Number of pages4
JournalArzneimittel-Forschung
Volume47
Issue number8
Publication statusPublished - 1997

Fingerprint

Gemfibrozil
Therapeutic Equivalency
Pharmacokinetics
Capsules
Area Under Curve
Plasmas
Analysis of variance (ANOVA)
Cross-Over Studies
Biological Availability
Analysis of Variance
Healthy Volunteers
High Pressure Liquid Chromatography
Confidence Intervals

Keywords

  • Antihyperlipaemic drug
  • Bioequivalence
  • CAS 25812-30-0
  • Clinical studies
  • Gemfibrozil
  • Innogem®
  • Pharmacokinetics

ASJC Scopus subject areas

  • Drug Discovery
  • Organic Chemistry
  • Chemistry(all)
  • Pharmacology

Cite this

Benkö, S., Drabant, S., Grézal, G., Ürmös, I., Csörgö, M., & Klebovich, I. (1997). Pharmacokinetic and bioequivalence study of two gemfibrozil preparations. Arzneimittel-Forschung, 47(8), 913-916.

Pharmacokinetic and bioequivalence study of two gemfibrozil preparations. / Benkö, Sarolta; Drabant, Sándor; Grézal, Gyula; Ürmös, Iván; Csörgö, Margit; Klebovich, I.

In: Arzneimittel-Forschung, Vol. 47, No. 8, 1997, p. 913-916.

Research output: Contribution to journalArticle

Benkö, S, Drabant, S, Grézal, G, Ürmös, I, Csörgö, M & Klebovich, I 1997, 'Pharmacokinetic and bioequivalence study of two gemfibrozil preparations', Arzneimittel-Forschung, vol. 47, no. 8, pp. 913-916.
Benkö S, Drabant S, Grézal G, Ürmös I, Csörgö M, Klebovich I. Pharmacokinetic and bioequivalence study of two gemfibrozil preparations. Arzneimittel-Forschung. 1997;47(8):913-916.
Benkö, Sarolta ; Drabant, Sándor ; Grézal, Gyula ; Ürmös, Iván ; Csörgö, Margit ; Klebovich, I. / Pharmacokinetic and bioequivalence study of two gemfibrozil preparations. In: Arzneimittel-Forschung. 1997 ; Vol. 47, No. 8. pp. 913-916.
@article{16aaec5dad58435b9d5d65a5709ba1c3,
title = "Pharmacokinetic and bioequivalence study of two gemfibrozil preparations",
abstract = "A comparative pharmacokinetic study has been performed in 19 healthy male volunteers in a single-dose, randomized, two way cross-over design with two preparations of gemfibrozil (CAS 25812-30-0) capsules each of them containing 300 mg active ingredient. The test preparation was Innogem{\circledR} 300 mg capsule. The plasma concentration of gemfibrozil was determined by a validated HPLC-UV analytical method. The statistical comparison of individual pharmacokinetic parameters (AUC0-16, AUC(0-∞), C(max), t(max)) Of the two capsule preparations was performed by three-way analysis of variance (ANOVA), Wilcoxon's, Westlake's, Schuirmann's and Hauck-Anderson's method as well as by the calculation of confidence intervals on the ratio of test/reference. The relativ bioavailability of the test preparation with respect to the reference preparation in terms of the AUC(0-∞) was 104.06 ± 21.61{\%}. No statistically significant difference was found between the pharmacokinetic parameters, calculated from plasma concentration-time curves, indicating that the two preparations were bioequivalent.",
keywords = "Antihyperlipaemic drug, Bioequivalence, CAS 25812-30-0, Clinical studies, Gemfibrozil, Innogem{\circledR}, Pharmacokinetics",
author = "Sarolta Benk{\"o} and S{\'a}ndor Drabant and Gyula Gr{\'e}zal and Iv{\'a}n {\"U}rm{\"o}s and Margit Cs{\"o}rg{\"o} and I. Klebovich",
year = "1997",
language = "English",
volume = "47",
pages = "913--916",
journal = "Drug Research",
issn = "2194-9379",
publisher = "Thieme",
number = "8",

}

TY - JOUR

T1 - Pharmacokinetic and bioequivalence study of two gemfibrozil preparations

AU - Benkö, Sarolta

AU - Drabant, Sándor

AU - Grézal, Gyula

AU - Ürmös, Iván

AU - Csörgö, Margit

AU - Klebovich, I.

PY - 1997

Y1 - 1997

N2 - A comparative pharmacokinetic study has been performed in 19 healthy male volunteers in a single-dose, randomized, two way cross-over design with two preparations of gemfibrozil (CAS 25812-30-0) capsules each of them containing 300 mg active ingredient. The test preparation was Innogem® 300 mg capsule. The plasma concentration of gemfibrozil was determined by a validated HPLC-UV analytical method. The statistical comparison of individual pharmacokinetic parameters (AUC0-16, AUC(0-∞), C(max), t(max)) Of the two capsule preparations was performed by three-way analysis of variance (ANOVA), Wilcoxon's, Westlake's, Schuirmann's and Hauck-Anderson's method as well as by the calculation of confidence intervals on the ratio of test/reference. The relativ bioavailability of the test preparation with respect to the reference preparation in terms of the AUC(0-∞) was 104.06 ± 21.61%. No statistically significant difference was found between the pharmacokinetic parameters, calculated from plasma concentration-time curves, indicating that the two preparations were bioequivalent.

AB - A comparative pharmacokinetic study has been performed in 19 healthy male volunteers in a single-dose, randomized, two way cross-over design with two preparations of gemfibrozil (CAS 25812-30-0) capsules each of them containing 300 mg active ingredient. The test preparation was Innogem® 300 mg capsule. The plasma concentration of gemfibrozil was determined by a validated HPLC-UV analytical method. The statistical comparison of individual pharmacokinetic parameters (AUC0-16, AUC(0-∞), C(max), t(max)) Of the two capsule preparations was performed by three-way analysis of variance (ANOVA), Wilcoxon's, Westlake's, Schuirmann's and Hauck-Anderson's method as well as by the calculation of confidence intervals on the ratio of test/reference. The relativ bioavailability of the test preparation with respect to the reference preparation in terms of the AUC(0-∞) was 104.06 ± 21.61%. No statistically significant difference was found between the pharmacokinetic parameters, calculated from plasma concentration-time curves, indicating that the two preparations were bioequivalent.

KW - Antihyperlipaemic drug

KW - Bioequivalence

KW - CAS 25812-30-0

KW - Clinical studies

KW - Gemfibrozil

KW - Innogem®

KW - Pharmacokinetics

UR - http://www.scopus.com/inward/record.url?scp=0030875048&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0030875048&partnerID=8YFLogxK

M3 - Article

C2 - 9296277

AN - SCOPUS:0030875048

VL - 47

SP - 913

EP - 916

JO - Drug Research

JF - Drug Research

SN - 2194-9379

IS - 8

ER -